Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors
Open Access
- 15 September 2004
- journal article
- clinical trial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (18), 6111-6118
- https://doi.org/10.1158/1078-0432.ccr-04-0422
Abstract
Purpose: The purpose is to investigate the safety and efficacy of i.p. topotecan and oral etoposide as salvage treatment for patients with platinum-resistant ovarian or primary peritoneal cancer.Keywords
This publication has 17 references indexed in Scilit:
- Bortezomib as a Potential Treatment for Prostate CancerCancer Research, 2004
- Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate CancerJournal of Clinical Oncology, 2004
- Phase II Trial of PS-341 in Patients With Renal Cell Cancer: A University of Chicago Phase II Consortium StudyJournal of Clinical Oncology, 2004
- The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood, 2003
- Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2002
- Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53Oncogene, 1998
- The Proteasome Is Involved in AngiogenesisBiochemical and Biophysical Research Communications, 1998
- Proteasome-Dependent Regulation of p21WAF1/CIP1ExpressionBiochemical and Biophysical Research Communications, 1996
- Specific inhibition of the chymotrypsin-like activity of the proteasome induces a bipolar morphology in neuroblastoma cellsChemistry & Biology, 1996
- Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27Science, 1995